Thanks, Guts, for telling the home truths. the overall picture for PXYN and SCRC is such that PXYN will inevitably experience difficulty in expanding and in improving its revenue situation, whereas SCRC has chalked up a sequential monthly and quarterly track record of revenues this year that is plain astonishing for an OTC stock. I welcome this kind of comparative discussion because it settles and clarifies the mind. Both stocks deserve attention and respect, but it's the comparative discussion that brings the distinctive features sharply into focus.